241 related articles for article (PubMed ID: 33000256)
21. Knockdown of A-kinase anchor protein 4 inhibits proliferation of triple-negative breast cancer cells
Jagadish N; Devi S; Gupta N; Suri V; Suri A
Tumour Biol; 2020 Apr; 42(4):1010428320914477. PubMed ID: 32342732
[TBL] [Abstract][Full Text] [Related]
22. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
Byerly JH; Port ER; Irie HY
Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444
[TBL] [Abstract][Full Text] [Related]
23. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
[TBL] [Abstract][Full Text] [Related]
24. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
25. CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.
Yang X; Zhao L; Pei J; Wang Z; Zhang J; Wang B
Breast Cancer Res Treat; 2020 Aug; 183(1):71-82. PubMed ID: 32601971
[TBL] [Abstract][Full Text] [Related]
26. circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.
Zheng SR; Huang QD; Zheng ZH; Zhang ZT; Guo GL
J Biochem; 2021 Jul; 169(5):601-611. PubMed ID: 33481008
[TBL] [Abstract][Full Text] [Related]
27. Obesity promotes radioresistance through SERPINE1-mediated aggressiveness and DNA repair of triple-negative breast cancer.
Su YH; Wu YZ; Ann DK; Chen JL; Kuo CY
Cell Death Dis; 2023 Jan; 14(1):53. PubMed ID: 36681663
[TBL] [Abstract][Full Text] [Related]
28. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
[TBL] [Abstract][Full Text] [Related]
29. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p.
Zang H; Li Y; Zhang X; Huang G
Thorac Cancer; 2020 Jul; 11(7):1891-1903. PubMed ID: 32445273
[TBL] [Abstract][Full Text] [Related]
30. Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer.
Yotsumoto F; Tokunaga E; Oki E; Maehara Y; Yamada H; Nakajima K; Nam SO; Miyata K; Koyanagi M; Doi K; Shirasawa S; Kuroki M; Miyamoto S
Mol Cancer Res; 2013 May; 11(5):506-17. PubMed ID: 23443317
[TBL] [Abstract][Full Text] [Related]
31. High expression of FUSE binding protein 1 in breast cancer stimulates cell proliferation and diminishes drug sensitivity.
Liu W; Xiong X; Chen W; Li X; Hua X; Liu Z; Zhang Z
Int J Oncol; 2020 Aug; 57(2):488-499. PubMed ID: 32626933
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway.
Zhang W; Cai J; Chen S; Zheng X; Hu S; Dong W; Lu J; Xing J; Dong Y
Mol Med Rep; 2015 Jul; 12(1):1506-14. PubMed ID: 25760096
[TBL] [Abstract][Full Text] [Related]
33. An isoflavone derivative potently inhibits the angiogenesis and progression of triple-negative breast cancer by targeting the MTA2/SerRS/VEGFA pathway.
Zhang X; Zou G; Li X; Wang L; Xie T; Zhao J; Wang L; Jiao S; Xiang R; Ye H; Shi Y
Cancer Biol Med; 2020 Aug; 17(3):693-706. PubMed ID: 32944400
[No Abstract] [Full Text] [Related]
34. HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance.
Zong B; Sun L; Peng Y; Wang Y; Yu Y; Lei J; Zhang Y; Guo S; Li K; Liu S
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036395
[TBL] [Abstract][Full Text] [Related]
35. Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer.
Chou CW; Huang YM; Chang YJ; Huang CY; Hung CS
Int J Med Sci; 2021; 18(12):2521-2531. PubMed ID: 34104083
[TBL] [Abstract][Full Text] [Related]
36. TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer.
Lin HY; Kuei CH; Lee HH; Lin CH; Chen YL; Chen CL; Lin YF
J Mol Med (Berl); 2020 Sep; 98(9):1255-1267. PubMed ID: 32671412
[TBL] [Abstract][Full Text] [Related]
37. LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ.
Wu H; Gu J; Zhou D; Cheng W; Wang Y; Wang Q; Wang X
J Cell Mol Med; 2020 Aug; 24(15):8589-8602. PubMed ID: 32652877
[TBL] [Abstract][Full Text] [Related]
38. Continuous Administration of Anti-VEGFA Antibody Upregulates PAI-1 Secretion from Ovarian Cancer Cells via miR-143-3p Downregulation.
Yagi T; Sawada K; Miyamoto M; Shimizu A; Oi Y; Toda A; Nakamura K; Kinose Y; Kodama M; Hashimoto K; Kimura T
Mol Cancer Res; 2023 Oct; 21(10):1093-1106. PubMed ID: 37327051
[TBL] [Abstract][Full Text] [Related]
39. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness.
Shin VY; Chen J; Cheuk IW; Siu MT; Ho CW; Wang X; Jin H; Kwong A
Cell Death Dis; 2019 Mar; 10(4):270. PubMed ID: 30894512
[TBL] [Abstract][Full Text] [Related]
40. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
